---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-032063"
form_type: "8-K"
ticker: "OMDA"
cik: "0001611115"
company_name: "Omada Health, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:45:52.044541+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Omada Health Q1 revenue $78M (+42% YoY); members top 1M, net loss narrows to $3M

## Summary
- Revenue $78M, up 42% YoY; total members 1.02M, up 51% YoY.
- Net loss $3M vs $9M in Q1 2025; adjusted EBITDA positive $1M vs -$4M.
- Joined Optum Rx Weight Engage; now relationships with all three top PBMs covering 80% of U.S. prescription claims.
- Gross margin 62% (non-GAAP 64%), up from 58% (non-GAAP 60%) YoY.
- Announced independent program administrator for Eli Lilly Employer Connect; GLP-1 Care Track data shows 1.8x weight loss.

## SEC filing metadata
- accession: 0001628280-26-032063
- form_type: 8-K
- ticker: OMDA
- cik: 0001611115
- company_name: Omada Health, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1611115/000162828026032063/0001628280-26-032063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1611115/000162828026032063/omda-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-032063
- JSON: https://secwatch.observer/filing/0001628280-26-032063.json
- Plain text: https://secwatch.observer/filing/0001628280-26-032063.txt

## Source-grounded claims
- claim_id: 81f6268374f1ff239ddd18baf70b90309c71c4c1
  claim: Omada Health, Inc. reported first quarter ended March 31, 2026 results: revenue $78 million in the first quarter, net income Net loss of $3 million in the first quarter.
  evidence_excerpt: million Total Members at the end of Q1, up 51% year over year, reinforcing Omada’s role as an integrated, multi-condition cardiometabolic platform operating at scale. • Revenue: $78 million in the first quarter, up 42% year over year. • Omada joined Optum Rx’s Weight Engage portfolio to help employers expand responsible, clinically supported access to GLP‐1 and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1611115/000162828026032063/0001628280-26-032063-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.